Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16


Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop.

Chang CM, Edwards SH, Arab A, Del Valle-Pinero AY, Yang L, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302. doi: 10.1158/1055-9965.EPI-16-0675. Epub 2016 Nov 9. Review.


Combined analysis of N'-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users.

Kotandeniya D, Carmella SG, Pillsbury ME, Hecht SS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 15;1007:121-6. doi: 10.1016/j.jchromb.2015.10.012. Epub 2015 Oct 31.


Quantitative analysis of 3'-hydroxynorcotinine in human urine.

Upadhyaya P, Hecht SS.

Nicotine Tob Res. 2015 May;17(5):524-9. doi: 10.1093/ntr/ntu206. Epub 2014 Oct 16.


Electronic nicotine delivery systems ("e-cigarettes"): review of safety and smoking cessation efficacy.

Harrell PT, Simmons VN, Correa JB, Padhya TA, Brandon TH.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):381-93. doi: 10.1177/0194599814536847. Epub 2014 Jun 4. Review.


Impact of neuro-psychological factors on smoking-associated lung cancer.

Schuller HM.

Cancers (Basel). 2014 Mar 13;6(1):580-94. doi: 10.3390/cancers6010580.


Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer.

Yuan JM, Butler LM, Stepanov I, Hecht SS.

Cancer Res. 2014 Jan 15;74(2):401-11. doi: 10.1158/0008-5472.CAN-13-3178. Epub 2014 Jan 9. Review.


Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans.

Knezevich A, Muzic J, Hatsukami DK, Hecht SS, Stepanov I.

Nicotine Tob Res. 2013 Feb;15(2):591-5. doi: 10.1093/ntr/nts172. Epub 2012 Aug 24.


Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai cohort study.

Hecht SS, Murphy SE, Stepanov I, Nelson HH, Yuan JM.

Cancer Lett. 2013 Jun 28;334(1):34-8. doi: 10.1016/j.canlet.2012.07.016. Epub 2012 Jul 20.


Muscle sarcomas and alopecia in A/J mice chronically treated with nicotine.

Galitovskiy V, Chernyavsky AI, Edwards RA, Grando SA.

Life Sci. 2012 Nov 27;91(21-22):1109-12. doi: 10.1016/j.lfs.2012.03.041. Epub 2012 Apr 12.


Urinary levels of the tobacco-specific carcinogen N'-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers.

Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I.

Carcinogenesis. 2011 Sep;32(9):1366-71. doi: 10.1093/carcin/bgr125. Epub 2011 Jul 6.


Electronic nicotine delivery systems: a research agenda.

Etter JF, Bullen C, Flouris AD, Laugesen M, Eissenberg T.

Tob Control. 2011 May;20(3):243-8. doi: 10.1136/tc.2010.042168. Epub 2011 Mar 17.


Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.

Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):91-100. doi: 10.1158/1055-9965.EPI-10-0349. Epub 2010 Nov 10. Erratum in: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1048.


Formation, repair, and genotoxic properties of bulky DNA adducts formed from tobacco-specific nitrosamines.

Peterson LA.

J Nucleic Acids. 2010 Sep 5;2010. pii: 284935. doi: 10.4061/2010/284935.


Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation.

Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS.

Addiction. 2010 Feb;105(2):343-55. doi: 10.1111/j.1360-0443.2009.02780.x.


Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products.

Stepanov I, Carmella SG, Briggs A, Hertsgaard L, Lindgren B, Hatsukami D, Hecht SS.

Cancer Res. 2009 Nov 1;69(21):8236-40. doi: 10.1158/0008-5472.CAN-09-1084. Epub 2009 Oct 20.

Supplemental Content

Support Center